TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30560679
Drug: Melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6 mg tablet)
Study: 18025625
Drug: Alfentanil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil and different doses of remifentanil
Study: 3160273
Drug: Anticholinergic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic treatment with ipratropium bromide (Atrovent)
Study: 26494833
Drug: Roxadustat with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat with oral iron
Study: 24346757
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg once daily for 11 days
Study: 24160674
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging intervention to collect daily alcohol consumption data
Study: 24160674
Drug: Text delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text delivered intervention on monthly alcohol expenditure
Study: 18167173
Drug: cis-9, trans-11-conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis-9, trans-11-conjugated linoleic acid (CLA) 2 g/d for 12 weeks
Study: 14624189
Drug: Olanzapine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10-20 mg/d)
Study: 10982347
Drug: IFN induction
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN induction (daily) therapy
Study: 10982347
Drug: IFN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN plus ribavirin combination therapy
Study: 1462021
Drug: Nebulized fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized fenoterol (5 mg)
Study: 7809438
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (5 mg)
Study: 16236844
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (0.5 mg)
Study: 27746377
Drug: Intra-articular corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular corticosteroid injection followed by exercise therapy
Study: 27746377
Drug: Intra-articular saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular saline injection followed by exercise therapy
Study: 23837414
Drug: Combination (aromatherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (aromatherapy and hand massage)
Study: 17314262
Drug: Bar on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bar on 4 implants
Study: 17314262
Drug: Bar on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bar on 2 implants
Study: 17314262
Drug: Ball attachments
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ball attachments on 2 implants
Study: 9886517
Drug: LNG rod
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG rod implants
Study: 9886517
Drug: Norplant capsules
Normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norplant capsules
Study: 8027856
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus trace minerals (1000 mg elemental Ca/d, 15.0 mg zinc/d, 5.0 mg manganese/d, 2.5 mg copper/d)
Study: 8027856
Drug: Calcium only
Normalized name: Calcium only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium only (1000 mg elemental Ca/d)
Study: 2755611
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of amniotic membrane
Study: 28617537
Drug: Spirulina (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina (2 g daily for three months)
Study: 17902008
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sertraline (25 mg/day for 2 days, then 50 mg from day 3 to 90) and buspirone (5 mg three times a day for 7 days, then 10 mg from day 8 to 90) plus cognitive-behavioral treatment
Study: 14659445
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 200 mg disodium clodronate
Study: 9135185
Drug: Rocuronium (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (twice ED95 dose)
Study: 3163212
Drug: High-dose Ara-C
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-dose Ara-C (HiDAC)
Study: 3163212
Drug: Sequential asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential asparaginase
Study: 30654929
Drug: Conservative CTO
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative CTO treatment (n=154)
Study: 23649042
Drug: Doxycycline hyclate
Normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline hyclate (20 mg, twice daily for 2 years)
Study: 15950714
Drug: Deferred antiepileptic
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred antiepileptic drug treatment
Study: 10216073
Drug: rhTPO and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTPO and G‐CSF
Study: 8682055
Drug: Spironolactone (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (12.5, 25, 50, or 75 mg per day)
Study: 2184556
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg atenolol (Tenormin)
Study: 376390
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg daily for 1 year maintenance therapy
Study: 17061961
Drug: Zolpidem-MR 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem-MR 6.25 mg
Study: 16702893
Drug: Zolpidem-MR 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem-MR 12.5 mg
Study: 11848519
Drug: Concurrent cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin-based chemotherapy and irradiation
Study: 8342825
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of 2.5% thiopental
Study: 8342825
Drug: 0.7 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g/kg alcohol
Study: 31538887
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mitiglinide and voglibose
Study: 23221670
Drug: Device-assisted ultrasound-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device-assisted ultrasound-guided injection
Study: 18062845
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone 16 mg with 0% alcohol
Study: 18062845
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone 16 mg with 4% alcohol
Study: 18062845
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone 16 mg with 20% alcohol
Study: 18062845
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone 16 mg with 40% alcohol
Study: 12366728
Drug: Topiramate 50
Normalized name: topiramate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 50 mg
Study: 16432681
Drug: Topiramate (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (both doses)
Study: 3147046
Drug: Nalmefene (opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene (opioid antagonist)
Study: 27609188
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 6 ml/kg
Study: 27609188
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 10 ml/kg
Study: 23994882
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (ISMN) 20 mg retarded release orally twice per day, n=30
Study: 11694921
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Resection of any inferior clavicle spur, violation of the inferior joint capsule, and removal of articular cartilage to a level adjacent with the resected acromion
Study: 9400772
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% dexamethasone (DMS)
Study: 26520171
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% fluorometholone (FML)
Study: 24271093
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (CPT) for airway clearance
Study: 18441854
Drug: BPO 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPO 5% monotherapy
Study: 18441854
Drug: BPO 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPO 10% monotherapy
Study: 10165114
Drug: Standard actuator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard actuator with inhaled beclomethasone dipropionate (0.5 mg twice daily)
Study: 24943285
Drug: HAD (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAD (20 g beef per day)
Study: 24943285
Drug: BOLD diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOLD diet (113 g beef per day)
Study: 24943285
Drug: DASH diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH diet (28 g beef per day)
Study: 20629812
Drug: Any medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any medication change or therapeutic lifestyle changes counseling
Study: 12020302
Drug: CEEs, 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEEs, 0.45 mg/d and MPA, 2.5 mg/d
Study: 12020302
Drug: CEEs, 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEEs, 0.45 mg/d and MPA, 1.5 mg/d
Study: 12020302
Drug: CEEs, 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEEs, 0.3 mg/d and MPA, 1.5 mg/d
Study: 23326930
Drug: Test treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test treatment
Study: 7712301
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg daily for 4 weeks) + Amoxycillin (1 g three times daily for 2 weeks) + Metronidazole (1 g daily for 2 weeks)
Study: 7712301
Drug: Omeprazole +
Normalized name: Omeprazole + SyrSpend SF Alka
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole + Antibiotics
Study: 238790
Drug: Clemastine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine (1 mg b.d.)
Study: 238790
Drug: Chlorpheniramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (4 mg b.d.)
Study: 18227366
Drug: Bupropion hydrochloride
Normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion hydrochloride therapy with smoking counseling
Study: 7870745
Drug: Mianserin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (60 mg/day in three oral doses)
Study: 7870745
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 mg/day in three oral doses)
Study: 1958436
Drug: Standard nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nicardipine (STD) 30 mg three times daily for 28 days
Study: 1958436
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release nicardipine (SR) 60 mg twice daily for 28 days
Study: 616212
Drug: CO inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO inhalation (1100 ppm CO-air mixture)
Study: 27591965
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of disclaimer label and pre-exposure message
Study: 26338956
Drug: Ivabradine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine at 7.5 mg twice daily
Study: 18550399
Drug: M6G (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: M6G (10 mg/70 kg and 20 mg/70 kg)
Study: 17803344
Drug: Ulinastatin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin therapy (30,000 U/kg/day for 3 days)
Study: 17803344
Drug: IVIG therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG therapy (1 g/kg/dose)
Study: 14729733
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg orally every 12 h for a total of six doses
Study: 17019296
Drug: High NaHCO3
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High NaHCO3 intake (0.5 g x kg(‐1) x d(‐1))
Study: 8959154
Drug: Intravenous bacille
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bacille Calmette‐Guérin (BCG) vaccination
Study: 3911963
Drug: suprofen syrup
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: suprofen syrup
Study: 3911963
Drug: paracetamol syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: paracetamol syrup
Study: 26644241
Drug: Eplerenone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (50 mg, oral)
Study: 24041860
Drug: Tramadol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (2 mg/kg-2 ml)
Study: 24041860
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg-2 ml)
Study: 24041860
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 ml serum physiologic)
Study: 12576897
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection (20 to 30 U, approximately 0.3 U/kg)
Study: 10494574
Drug: Hydrocortisone 20
Normalized name: hydrocortisone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 20 mg administered twice daily for 10 days
Study: 7356891
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg propranolol
Study: 11422094
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg metoprolol
Study: 22958078
Drug: Tadalafil 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5.0 mg
Study: 18286351
Drug: Low-dose steroid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose steroid therapy (prednisolone 0.4 mg/kgBW/day, tapered to 5-10 mg/day over 24 months)
Study: 18286351
Drug: Low-dose steroid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose steroid therapy (prednisolone)
Study: 18286351
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dipyridamole or zilazep hydrochloride 150 or 300 mg/day)
Study: 9858113
Drug: Dexamethasone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (3 mg/day)
Study: 14529881
Drug: Reduced CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced CsA dose (5 mg/kg/d) and daclizumab (group A, n = 16)
Study: 14529881
Drug: Normal CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal CsA dose (10 mg/kg/day) without daclizumab (group B, n = 16)
Study: 14529881
Drug: Reduced CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced CsA dose (5 mg/kg/d) and daclizumab (group A)
Study: 14529881
Drug: Normal CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal CsA dose (10 mg/kg/day) without daclizumab (group B)
Study: 11113421
Drug: sublingual estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual estradiol 17beta
Study: 1532534
Drug: Cilazapril 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 5.0 mg/day + Hydrochlorothiazide 12.5 mg/day
Study: 3921597
Drug: 0.02 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg/kg NAL infusion
Study: 3921597
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg NAL infusion
Study: 3921597
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg NAL infusion
Study: 3921597
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of NAL
Study: 3921597
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of NAL
Study: 27687342
Drug: Multisource feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisource feedback with monthly coaching meetings
Study: 27687342
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no monthly coaching meetings)
Study: 18796350
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (5 g) before each chemotherapy course and magnesium subcarbonate (500 mg) three times per day orally during treatment intervals
Study: 15812765
Drug: Prophylactic brimonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic brimonidine in patients on anticoagulant or antiplatelet treatment
Study: 10524634
Drug: UDCA 600
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 600 mg/day
Study: 10524634
Drug: UDCA 0
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 0 mg/day (placebo)
Study: 20932411
Drug: Cetrorelix pamoate
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix pamoate (various dosages: 30 + 30 mg, 30 + 30 + 30 mg, 60 + 30 mg, 60 + 60 mg)
Study: 12386644
Drug: High-profile infusion
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-profile infusion (total dose of rilmenidine, 3.3 mg)
Study: 12386644
Drug: Low-profile infusion
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-profile infusion (total dose of rilmenidine, 1.45 mg)
Study: 7748969
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg loading dose (LD) of gentamicin
Study: 7748969
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg every 12, 18 or 24 h (control group)
Study: 22367417
Drug: Citalopram plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram plus paliperidone (20 mg/day + 3 mg/day)
Study: 15877299
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg/d
Study: 24528686
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg/d
Study: 11952433
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion rate of 1.0 ml/s
Study: 11952433
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion rate of 0.2 ml/s
Study: 7542473
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus interferon (IFN)
Study: 2093956
Drug: Weekly interruption
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly interruption digoxin dosage (2 days interruption per week)
Study: 2093956
Drug: Continuous digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous digoxin dosage (uninterrupted)
Study: 444354
Drug: Cinnarizine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine (75 mg) in capsule form
Study: 444354
Drug: Cinnarizine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine (75 mg) in tablet form
Study: 444354
Drug: Cinnarizine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine (75 mg)
Study: 30602032
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg every 2 months
Study: 26430694
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg/day, four doses of 625 mg calcium carbonate for 1 month)
Study: 24219374
Drug: Iron-fortified flavored
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified flavored skim milk (500 mL/day)
Study: 24219374
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and vitamin D-fortified flavored skim milk (500 mL/day)
Study: 22517917
Drug: SPARX (computerised
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPARX (computerised cognitive behavioural therapy)
Study: 22517917
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (face to face counselling)
Study: 17598698
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available original preparation (reference)
Study: 15510930
Drug: Premelle (Premarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premelle (Premarin 0.625 mg plus medroxyprogesterone acetate 2.5 mg/tablet orally)
Study: 8301442
Drug: 2.5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml/kg surfactant
Study: 8301442
Drug: 5.0 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 ml/kg surfactant
Study: 8301442
Drug: Air placebo
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air placebo (5.0 ml/kg)
Study: 8301442
Drug: Standard two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard two 5.0 ml/kg rescue doses
Study: 30089410
Drug: Carnosine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnosine supplementation (500 mg daily for two months)
Study: 25439118
Drug: Intravenous self‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous self‐controlled analgesia (IA group, n = 24)
Study: 25439118
Drug: Intravenous self‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous self‐controlled analgesia (IA group)